Tectonic Therapeutic, Inc.: Form 10-K for the period ended Dec 31, 2019
Filed with the SEC on Mar 16, 2020 and accepted by EDGAR at Mar 16, 2020, 16:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2019-01-01 to 2019-12-31 | $55.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2019-01-01 to 2019-12-31 | −$75.8m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2019-01-01 to 2019-12-31 | −$73.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2019-01-01 to 2019-12-31 | −$2.66 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2019-01-01 to 2019-12-31 | −$67.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2019-01-01 to 2019-12-31 | $1.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-12-31 | $187.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $195.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $200.5m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $14.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $14.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-12-31 | $186.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-011144. Last ingested by Listed: Nov 5, 2026, 19:21 ET. Listed shows no prices and gives no investment advice.